Literature DB >> 19775995

Angiogenesis and ovarian cancer.

César Gómez-Raposo1, Marta Mendiola, Jorge Barriuso, Enrique Casado, David Hardisson, Andrés Redondo.   

Abstract

Ovarian carcinoma is the most important cause of gynaecological cancer-related mortality in Western societies. The age at diagnosis, extent of disease (as expressed by FIGO state), success of primary surgery and the histopathological features of the tumour are important prognostic markers. The majority of patients with ovarian cancer present with advanced disease (FIGO stage III/IV) and in this group of patients the median survival is only three years. New treatment approaches are therefore required to improve outcome in this disease. Angiogenesis, the development of a neovascular blood supply, is a critical step in the propagation of malignant tumour growth and metastasis and represents a promising target. This review will focus on angiogenesis, VEGF biology and the potential value of angiogenic factors with prognostic value in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775995     DOI: 10.1007/s12094-009-0406-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  71 in total

1.  Angiogenesis in primary and metastatic epithelial ovarian carcinoma.

Authors:  O Abulafia; W E Triest; D M Sherer
Journal:  Am J Obstet Gynecol       Date:  1997-09       Impact factor: 8.661

2.  Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Alan Hutson; Sarah M Bean; Laura J Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2009-01-09       Impact factor: 5.482

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

4.  A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Authors:  C Q Lin; J Singh; K Murata; Y Itahana; S Parrinello; S H Liang; C E Gillett; J Campisi; P Y Desprez
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

5.  The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer.

Authors:  Y Nakanishi; J Kodama; M Yoshinouchi; K Tokumo; S Kamimura; H Okuda; T Kudo
Journal:  Int J Gynecol Pathol       Date:  1997-07       Impact factor: 2.762

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients.

Authors:  Ben Davidson; Iris Goldberg; Reuven Reich; Liora Tell; Hiep Phuc Dong; Claes G Trope'; Bjørn Risberg; Juri Kopolovic
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

8.  Genes that distinguish physiological and pathological angiogenesis.

Authors:  Steven Seaman; Janine Stevens; Mi Young Yang; Daniel Logsdon; Cari Graff-Cherry; Brad St Croix
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

9.  Inhibition of tumor growth and angiogenesis by soluble EphB4.

Authors:  Georg Martiny-Baron; Thomas Korff; Florence Schaffner; Norbert Esser; Stefan Eggstein; Dieter Marmé; Hellmut G Augustin
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

10.  The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.

Authors:  X B Trinh; W A A Tjalma; P B Vermeulen; G Van den Eynden; I Van der Auwera; S J Van Laere; J Helleman; E M J J Berns; L Y Dirix; P A van Dam
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  24 in total

1.  Id-1 expression and prognosis in cancer: do antibodies matter?

Authors:  Ignacio Gil-Bazo; Mariano Ponz-Sarvisé; Angel Panizo-Santos; Alfonso Calvo
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

2.  Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

Authors:  Antonio González Martín
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

3.  Effect of 15-lipoxygenase metabolites on angiogenesis: 15(S)-HPETE is angiostatic and 15(S)-HETE is angiogenic.

Authors:  Sasikumar J Soumya; Sheela Binu; A Helen; K Anil Kumar; P Reddanna; Perumana R Sudhakaran
Journal:  Inflamm Res       Date:  2012-03-27       Impact factor: 4.575

4.  Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Authors:  Vianey Gonzalez-Villasana; Enrique Fuentes-Mattei; Cristina Ivan; Heather J Dalton; Cristian Rodriguez-Aguayo; Ricardo J Fernandez-de Thomas; Burcu Aslan; Paloma Del C Monroig; Guermarie Velazquez-Torres; Rebecca A Previs; Sunila Pradeep; Nermin Kahraman; Huamin Wang; Pinar Kanlikilicer; Bulent Ozpolat; George Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2015-01-16       Impact factor: 12.531

5.  Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.

Authors:  Nirupama Deshpande; Ying Ren; Kira Foygel; Jarrett Rosenberg; Jürgen K Willmann
Journal:  Radiology       Date:  2011-03       Impact factor: 11.105

Review 6.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

7.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Authors:  Lokesh Jain; Tristan M Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Journal:  J Exp Clin Cancer Res       Date:  2010-07-14

8.  Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Authors:  Marc A Becker; Thahir Farzan; Sean C Harrington; James W Krempski; S John Weroha; Xiaonan Hou; Kimberly R Kalli; Tai W Wong; Paul Haluska
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

9.  MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1β induced in human endometriosis stromal cells in vitro.

Authors:  Fengying Huang; Jing Cao; Qiuhong Liu; Ying Zou; Hongyun Li; Tuanfang Yin
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

10.  The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

Authors:  Arthur B McKie; Sebastian Vaughan; Elisa Zanini; Imoh S Okon; Louay Louis; Camila de Sousa; Mark I Greene; Qiang Wang; Roshan Agarwal; Dmitry Shaposhnikov; Joshua L C Wong; Hatice Gungor; Szymon Janczar; Mona El-Bahrawy; Eric W-F Lam; Naomi E Chayen; Hani Gabra
Journal:  Cancer Discov       Date:  2012-02       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.